Stocksigma LogoStocksigma Logo

Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026

Sun Pharma announced updated long-term pivotal trial data for UNLOXCYT (cosibelimab-ipdl) in advanced cutaneous squamous cell carcinoma at ESMO on 24th

Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026

Sun Pharmaceutical Industries Ltd · Press Release · 23 Oct 2026, 11:31 pm

Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026 Sun Pharma announced updated long-term pivotal trial data for UNLOXCYT (cosibelimab-ipdl) in advanced cutaneous squamous cell carcinoma at ESMO on 24th Oct'26. In locally advanced CSCC, the drug achieved a 53.1% objective response rate (ORR) with a 34.4% complete response (CR) and a median progression-free survival (PFS) of 37.3 months. Metastatic CSCC cohorts recorded ORRs of 44.4% to 51.3% (CRs of 16.7%–20.6%). Estimated 24-month response durability ranged between 69% and 82%, alongside a favorable safety profile showing 2.9% Grade 3 immune-related adverse events.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements